Related Experiment Video
Updated: Aug 27, 2025

A Method for Measuring RNA N6-methyladenosine Modifications in Cells and Tissues
Published on: December 5, 2016
N6-methyladenosine in hematological malignancies: a concise review
Wan-Jie Wang1, Ting-Ting Xu, Jing Bao
1Department of Hematology, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Purpose Of Review:
Hematological malignancies are a kind of systemic cancers mostly related to abnormal differentiation of blood stem cells. Because of the poor prognosis, chemotherapy resistance and common recurrence, new mechanisms and treatment therapies are looking forward to be discovered.
Recent Findings:
Over the years, epigenetic abnormalities have been known to act a key part in occurrence and development of hematological tumors. In the internal modifications on long noncoding eukaryotic mRNA, there is a common type called N6-methyladenosine that can change the expression of target genes and participate in the translation, degradation and splicing of mRNA. M6A is related to a wealth of cancers, such as HNRNPA2B1's elevation in multiple myeloma, METTLE3's elevation in acute myeloid leukemia and lung cancer. Immune cells, playing a significant role in hematological cancers, can also be regulated by m6A.
Summary:
In the review, we summarized the recent progress on hematological malignancies associating with m6A and immune cells, which may offer a new road for the treatment of them.
Related Concept Videos
Biosynthesis of Nucleic Acids
RNA Editing
Regulation of Hematopoietic Stem Cells
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
RNA Stability
mRNA Stability and Gene Expression
Cis-acting Elements involved in mRNA stability

